Desideratum for Evidence Based Epidemiology

[1]  T. Dawber,et al.  The Framingham Study , 2014 .

[2]  William DuMouchel,et al.  Interpreting observational studies: why empirical calibration is needed to correct p-values , 2013, Statistics in medicine.

[3]  M. Schuemie,et al.  Variation in Choice of Study Design: Findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) Survey , 2013, Drug Safety.

[4]  Patrick B. Ryan,et al.  Empirical Performance of a Self-Controlled Cohort Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[5]  Brent I. Fox,et al.  How Well Do Various Health Outcome Definitions Identify Appropriate Cases in Observational Studies? , 2013, Drug Safety.

[6]  M. Schuemie,et al.  Defining a Reference Set to Support Methodological Research in Drug Safety , 2013, Drug Safety.

[7]  Martijn J Schuemie,et al.  Evaluating Performance of Risk Identification Methods Through a Large-Scale Simulation of Observational Data , 2013, Drug Safety.

[8]  William DuMouchel,et al.  Evaluation of Disproportionality Safety Signaling Applied to Healthcare Databases , 2013, Drug Safety.

[9]  Patrick B. Ryan,et al.  Managing Data Quality for a Drug Safety Surveillance System , 2013, Drug Safety.

[10]  David Madigan,et al.  Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[11]  David Madigan,et al.  Empirical Performance of the Self-Controlled Case Series Design: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[12]  M. Suchard,et al.  The Impact of Drug and Outcome Prevalence on the Feasibility and Performance of Analytical Methods for a Risk Identification and Analysis System , 2013, Drug Safety.

[13]  Patrick B. Ryan,et al.  Alternative Outcome Definitions and Their Effect on the Performance of Methods for Observational Outcome Studies , 2013, Drug Safety.

[14]  David Madigan,et al.  Empirical Performance of LGPS and LEOPARD: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[15]  David Madigan,et al.  Empirical Performance of the Calibrated Self-Controlled Cohort Analysis Within Temporal Pattern Discovery: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[16]  Martijn J. Schuemie,et al.  Replication of the OMOP Experiment in Europe: Evaluating Methods for Risk Identification in Electronic Health Record Databases , 2013, Drug Safety.

[17]  D. Madigan,et al.  Evaluating the impact of database heterogeneity on observational study results. , 2013, American journal of epidemiology.

[18]  V. Prasad,et al.  Prespecified falsification end points: can they validate true observational associations? , 2013, JAMA.

[19]  David Madigan,et al.  Empirical Performance of the Case–Control Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[20]  D. Madigan,et al.  Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership , 2012, Statistics in medicine.

[21]  Patrick B. Ryan,et al.  Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases , 2012, J. Biomed. Informatics.

[22]  S. Suissa.  Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer , 2012, Rambam Maimonides medical journal.

[23]  Rosa Gini,et al.  Electronic healthcare databases for active drug safety surveillance: is there enough leverage? , 2012, Pharmacoepidemiology and drug safety.

[24]  J. Ioannidis,et al.  Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. , 2012, Circulation research.

[25]  M. Hernán,et al.  Systematic Reviews and Meta-and Pooled Analyses Bias in Observational Studies of Prevalent Users : Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins , 2012 .

[26]  Malcolm Maclure,et al.  Design considerations in an active medical product safety monitoring system , 2012, Pharmacoepidemiology and drug safety.

[27]  A. Fourrier-Réglat,et al.  The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 1, 2012, Revision 2, 2013, Revision 3, 2014)). , 2012 .

[28]  Canary Wharf,et al.  The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) , 2012 .

[29]  Patrick B. Ryan,et al.  Validation of a common data model for active safety surveillance research , 2012, J. Am. Medical Informatics Assoc..

[30]  S. Stanley Young,et al.  Deming, data and observational studies , 2011 .

[31]  C. Lawton.  Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer , 2011 .

[32]  Gabriela Czanner,et al.  Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort , 2010, BMJ : British Medical Journal.

[33]  Jane M. Young,et al.  Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. , 2010, Journal of clinical epidemiology.

[34]  A. Pariente,et al.  Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? , 2009, Pharmacoepidemiology and drug safety.

[35]  Alexander M. Millkey.  The Black Swan: The Impact of the Highly Improbable , 2009 .

[36]  David J. Hand,et al.  Measuring classifier performance: a coherent alternative to the area under the ROC curve , 2009, Machine Learning.

[37]  James M. Robins,et al.  Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease , 2008, Epidemiology.

[38]  C. Bombardier,et al.  Methodological quality and homogeneity influenced agreement between randomized trials and nonrandomized studies of the same intervention for back pain. , 2008, Journal of clinical epidemiology.

[39]  J. Avorn.  In defense of pharmacoepidemiology--embracing the yin and yang of drug research. , 2007, The New England journal of medicine.

[40]  R. Tuma.  Statisticians set sights on observational studies. , 2007, Journal of the National Cancer Institute.

[41]  Frank de Vries,et al.  Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. , 2006, International journal of epidemiology.

[42]  P. Rothwell,et al.  Factors That Can Affect the External Validity of Randomised Controlled Trials , 2006, PLoS clinical trials.

[43]  D. Thomas.  Discussion on "Statistical Issues Arising in the Women's Health Initiative" , 2005 .

[44]  Garnet L Anderson,et al.  Statistical Issues Arising in the Women's Health Initiative , 2005, Biometrics.

[45]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[46]  K. Clauson.  Drug-Induced Diseases: Prevention, Detection, and Management , 2005 .

[47]  Karl R. Popper,et al.  Science : Conjectures and Refutations , 2005 .

[48]  Yi Xu,et al.  The copy-exactly ramp-up strategy: trading-off learning with process change , 2004, IEEE Transactions on Engineering Management.

[49]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[50]  C. Cooper,et al.  Use of Statins and Risk of Fractures , 2001 .

[51]  H Jick,et al.  HMG-CoA reductase inhibitors and the risk of fractures. , 2000, JAMA.

[52]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[53]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials , 2000, American journal of ophthalmology.

[54]  L. García-Rodríguez,et al.  Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. , 2000, Circulation.

[55]  T A Sheldon,et al.  A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. , 2000, Health technology assessment.

[56]  Chris J. McDonald,et al.  The Evolution of Intel s Copy EXACTLY ! Technology Transfer Method , 1998 .

[57]  J. Manson,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[58]  T. Kuhn.  The structure of scientific revolutions, 3rd ed. , 1996 .

[59]  P. Wilson,et al.  Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. , 1985, The New England journal of medicine.

[60]  T. Kuhn,et al.  The Structure of Scientific Revolutions. , 1964 .